C-IU8NShift Bioscience
cell rejuvenation, aging clocks, siRNA therapeutics
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
C-IU8Ncell rejuvenation, aging clocks, siRNA therapeutics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Shift Bioscience cell rejuvenation, aging clocks, siRNA therapeutics
Shift Bioscience targets the underlying cause of age-driven diseases: the aging cell. Its platform combines a novel aging clock, AC4, with a virtual cell model to discover cellular aging and rejuvenation targets. Its product program includes SB101, an anti-fibrotic siRNA therapeutic intended to reverse epigenetic aging clocks in multiple cell types, with initial opportunities in liver fibrosis.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Shift Bioscience — Early mechanism · Bottom quartile. Derived deterministically from 8 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic